« Back
Home /
20-HEDE

20-HEDE

Item no.	HY-101527-25mg
Manufacturer	MedChem Express
CASRN	240427-90-1
Amount	25 mg
Quantity options	100 mg 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	98.0
Citations	[1]Ming Yua . et al. Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur J Pharmacol. 2004 Feb 23;486(3):297-306.\|[2]Wei Yu, et al. Cytochrome P450 ω-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer. Cancer Chemother Pharmacol. 2011 Sep; 68(3): 619-29.\|[3]Anna Alexanian, et al. Down-regulation of 20-HETE Synthesis and Signaling Inhibits Renal Adenocarcinoma Cell Proliferation and Tumor Growth. Anticancer Res. 2009 October ; 29(10): 3819-3824.
Smiles	O=C(O)CCCC/C=C\CCCCCCC/C=C\CCCCO
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	WIT 002
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Others
Shipping Temperature	Blue Ice
Storage Conditions	-20°C, 3 years (Powder)
Molecular Weight	324.50
Product Description	20-HEDE (WIT 002) is an antagonist of 20-hydroxyeicosatetraenoic acid (20-HETE).
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 180 mg/mL
Manufacturer - Pathway	Others
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-101527-25mg-safety-datasheet.pdf